RE: Recent developments17 Apr 2024 10:51
I would agree that the Stalicla deal is still extremely important, particularly for the short term, however I do not agree that if the deal was pulled it would be game over. With the cash available from the raise, Evgen would still have time to complete on another deal. However, Stalicla pulling out would put significant pressure on not only the share price, but also management. The lack of any deals subsequent to Stalicla would raise concerns around the likelihood of another one being competed in time before cash runs out.
I do have to agree that it seems like Stalicla wanted SFX-01 on the cheap, a feeling I had when the news first dropped of the dispute, but maybe we're being too cynical and there really is something that Stalicla believe Evgen has missed to receive the payment. And if this was the reason for the slow payment from Stalicla, I would imagine that they will now rethink as the possibility of getting SFX-01 on the cheap has passed for now. With enough cash for circa two years, administration is off the cards for now and I doubt the majority of investors would support a lowball take-over bid. An offer of a least 5p may get support, but if management are confident in their ability to ‘add shareholder value’ over the next few years, than they may not recommend such an offer to shareholders.
I do not, however, agree that losing the Stalicla deal would benefit Evgen, such beliefs, in my opinion, are fanciful at best. The Stalicla deal is only for indications in neurodevelopmental disorders and so does not limit the ability to licence SFX-01 for other indications. Throughout the rest of the year I would like to see the Stalicla issues resolved and another deal completed on for confidence to return.